Biologics and Conjugates CDMO Services

Optimization of Synthetic Process and Metal-Chelation Impurity Control Strategy for Complex Peptide-based RDCs

It fully demonstrates the strength of Porton's one-stop RDC service platform, excellent project management capabilities, and efficient production and operation.

More

The Perfect Integration of Immobilized Enzymes and Flow Chemistry: A Powerful Booster for the Commercialization of Biocatalysis Technology

Adhering to Porton’s core value of “Pursuing Excellence”, Porton biocatalysis team has designated "enzyme immobilization technology and its industrialization" as a core strategic technology.

More

Process Simulation Platform: Enabling Process Development and Scale-up of Active Pharmaceutical Ingredients

Porton Crystallization team has the capability to perform process simulation of unit operations, including solvent swap, crystallization, filtration and drying.

More

Optimizing Process Chemistry for Enhanced Pharmaceutical Manufacturing

Process Chemistry Optimization | Pharma Manufacturing

More

Expert Q&A: How to Efficiently Apply Preparative Chromatography in Drug Research

How to Efficiently Apply Preparative Chromatography in Drug Research

More

Biocatalysis: A Powerful and Possible Greener Tool for Chemists in the Pharmaceutical Industry

End-to-end Enzyme Solutions Efficient Screening & process Development Comprehensive Quality Control Extensive Successful Applications Cases Technological Innovation Enabled Cost Savings

More

Expert Q&A: Molecular Simulation and Data Science Support of Porton

Explore virtual screening duration, differences from property optimization, and crystal structure requirements for impurity rejection calculations.

More

Selecting the Right Solid Form-Faster, Smarter, Better

At Porton J-Star, we employ an integrated approach to identify and select the most suitable solid form for development (Figure 2). We conduct effective screen and rigorous assessments for polymorphs, salts, cocrystals, as well as amorphous solid dispersions, by applying our comprehensive expertise and experience.

More

Challenges and Advances in CMC Process Development of BsADCs

Antibody drug conjugates (ADCs) have seen significant breakthroughs and reached numerous milestones since 2000 when the first ADC was approved by the FDA and have shown great promise for the treatment of cancer. First generation ADCs were designed to use the affinity of an antibody towards a specific cellular target to bring the cytotoxic payload to the tumor, for example. However, some level of off-target toxicity was often seen with many ADCs because other cellular interactions could occur prior to the payload physically reaching its intended target or the payload could cleave off. These events could lead to unintended death of non-cancerous cells.

More

Preformulation Strategy- Inception to Completion

Drug discovery is an exceedingly complex process. Discovering a new chemical entity is in itself a huge accomplishment, which is often possible only after almost two decades of hard experimental work as well as advanced simulation efforts. Therefore, the next stage of the process, determination of toxicity becomes even more crucial as most new chemical entities (NCE) are disqualified if the NCE shows a potential toxic effect, despite any possible therapeutic effect.

More

Efficacy and Safety - Guidelines for Clinical In-use Stability Studies of ADCs

Antibody-drug conjugates (ADCs) consist of three parts: antibody, linker, and payload. This special combination enables ADCs to selectively target tumor cells and release cytotoxic drugs, but they face many stability challenges during manufacture, storage, and clinical use. In this paper, the drug product development team at Porton (hereinafter referred to as "we") discusses the necessary clinical in-use stability studies for ADCs.

More

Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development

Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development

More